Group 1 - Recent surge in innovative pharmaceutical stocks, with notable increases: Four Seasons Pharmaceutical up 8% to HKD 1.62, Hengrui Medicine up 6.46% to HKD 85.7, and WuXi AppTec up 5.46% to HKD 64.65 [1] - Foreign investments in Chinese innovative drug companies have intensified, with Singapore's GIC increasing its stake in Hengrui Medicine by acquiring 40.22 million shares at an average price of HKD 12.7133, totaling approximately HKD 5.11 billion [1] - GIC also purchased 80.4 million shares of Base Pharmaceuticals for HKD 635 million, raising its stake to 5.49%, while BlackRock acquired a 5.1% stake in 3SBio [1] Group 2 - Domestic innovative drug licensing has seen rapid growth, with 83 licensing agreements totaling USD 84.531 billion and upfront payments of USD 4.321 billion reported this year [2] - The upcoming World Conference on Lung Cancer (WCLC) from September 6-9, 2025, will feature 35 oral presentations by Chinese scholars, highlighting the anticipation for clinical data on domestic new drugs [2] - There is optimism for the value recovery of core assets in the second half of the year, as noted by Zhongyou Securities [2]
创新药延续近期涨势 外资密集举牌中国创新药企 机构看好下半年核心资产价值回归
Zhi Tong Cai Jing·2025-09-03 05:59